Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Capricor Therapeutics (CAPR) over the last 8 years, with Q3 2025 value amounting to $12.0 million.

  • Capricor Therapeutics' Current Deferred Revenue fell 860.98% to $12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 million, marking a year-over-year decrease of 860.98%. This contributed to the annual value of $12.0 million for FY2024, which is 5055.72% down from last year.
  • Latest data reveals that Capricor Therapeutics reported Current Deferred Revenue of $12.0 million as of Q3 2025, which was down 860.98% from $12.0 million recorded in Q2 2025.
  • In the past 5 years, Capricor Therapeutics' Current Deferred Revenue registered a high of $31.0 million during Q1 2023, and its lowest value of $9.7 million during Q1 2022.
  • Moreover, its 4-year median value for Current Deferred Revenue was $15.7 million (2022), whereas its average is $17.9 million.
  • Per our database at Business Quant, Capricor Therapeutics' Current Deferred Revenue surged by 21884.82% in 2023 and then crashed by 5055.72% in 2024.
  • Over the past 4 years, Capricor Therapeutics' Current Deferred Revenue (Quarter) stood at $18.0 million in 2022, then soared by 34.98% to $24.3 million in 2023, then crashed by 50.56% to $12.0 million in 2024, then changed by 0.0% to $12.0 million in 2025.
  • Its Current Deferred Revenue was $12.0 million in Q3 2025, compared to $12.0 million in Q2 2025 and $12.0 million in Q1 2025.